The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1300
December 1, 2008
View Complete Issue         Table of Contents 2019 
Alvimopan (Entereg) for Postoperative Ileus
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Alvimopan (Entereg) for Postoperative Ileus
December 1, 2008 (Issue: 1300)
The FDA has approved the marketing of alvimopan (Entereg - Adolor/GlaxoSmithKline), a selective muopioid receptor antagonist, for oral treatment of postoperative ileus after bowel resection. The only other drug in this class available in the US is...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Alvimopan (Entereg) for Postoperative Ileus
Article code: 1300a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.